Reflux Esophagitis Phase III Study (Maintenance Treatment)
NCT ID: NCT00634114
Last Updated: 2010-06-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
540 participants
INTERVENTIONAL
2008-01-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reflux Esophagitis Phase III Study (Initial Treatment)
NCT00633932
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
NCT01669811
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
NCT01397084
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
NCT00644735
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
NCT01249651
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Esomeprazole and Omeprazole
Esomeprazole
10mg once daily oral administration
Omeprazole
10mg once daily oral administration
2
Esomeprazole
Esomeprazole
20mg once daily oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Esomeprazole
10mg once daily oral administration
Esomeprazole
20mg once daily oral administration
Omeprazole
10mg once daily oral administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with endoscopically verified healed Reflux Esophagitis by EGD receiving general treatment with PPI
Exclusion Criteria
* Use of any PPI from 14 days before EGD performed at the screening visit to the day of randomisation.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maotsugu Oyama, MD, PhD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Akita, Akita, Japan
Research Site
Kashiwa, Chiba, Japan
Research Site
Kisarazu, Chiba, Japan
Research Site
Kōriyama, Fukishima, Japan
Research Site
Nihonmatsu, Fukishima, Japan
Research Site
Nishishirakawa, Fukishima, Japan
Research Site
Fukuoika, Fukuoka, Japan
Research Site
Fukuoka, Fukuoka, Japan
Research Site
Kurume, Fukuoka, Japan
Research Site
Nukaya, Fukuoka, Japan
Research Site
Fukuoka, Fukuolka, Japan
Research Site
Kōriyama, Fukushima, Japan
Research Site
Shirakawa, Fukushima, Japan
Research Site
Sugawa, Fukushima, Japan
Research Site
Gifu, Gifu, Japan
Research Site
Maebashi, Gunma, Japan
Research Site
Yasunaka, Gunma, Japan
Research Site
Sapporo, Hokkaido, Japan
Research Site
Hitachi, Ibaraki, Japan
Research Site
Mito, Ibaraki, Japan
Research Site
Tsukuba, Ibaraki, Japan
Research Site
Sakaidechō, Kagawa-ken, Japan
Research Site
Takamatsu, Kagawa-ken, Japan
Research Site
Fujisawa, Kanagawa, Japan
Research Site
Kawasaki, Kanagawa, Japan
Research Site
Sagamihara, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Kyoto, Kyoto, Japan
Research Site
Shibata, Myagi, Japan
Research Site
Kiso, Nagano, Japan
Research Site
Matsumoto, Nagano, Japan
Research Site
Ōita, Oita Prefecture, Japan
Research Site
Fujiidera, Osaka, Japan
Research Site
Toyonaka, Osaka, Japan
Research Site
Shizuoka, Shizuoka, Japan
Research Site
Ohtawara, Tochigi, Japan
Research Site
Toshima-ku, Tokayo, Japan
Research Site
Adachi City, Tokyo, Japan
Research Site
Hachiōji, Tokyo, Japan
Research Site
Kiyose, Tokyo, Japan
Research Site
Setagaya City, Tokyo, Japan
Research Site
Shinagawa, Tokyo, Japan
Research Site
Tottori-shi, Tottori, Japan
Research Site
Shimonoseki, Yamaguchi, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D961HC00006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.